69th DCC Recommends Mandatory Public Disclosure of Suspended and Cancelled Drug Licenses Vaayath Regulatory Desk | Drugs Consultative Committee, 69th Meeting | Held on 24.06.2026 The Drugs Consultative Committee (DCC), at its 69th meeting held on 24.06.2026, took up an…
Recent Post
- DCC Recommends Comprehensive Regulatory Mechanism to Curb Unapproved Drugs and FDCs
- DCC Recommends Mandatory Public Disclosure of Suspended and Cancelled Drug Licenses
- D&C Amended to Cover Licensing of Stem Cell Products, Gene Therapeutics and Xenografts
- Schedule H2 Expanded: Antimicrobials and Many Other Drugs Now Under Stricter Controls
- CDSCO Restricts IVF Supplies to Registered ART Centres
